Home   ->   news   ->   Press Releases

Press Releases

WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S..

SHANGHAI, May 10, 2016 -- WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.

TESARO, Inc. is an oncology-focused biopharmaceutical company based in Waltham, MA. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3. 

“We are pleased to be working with WuXi on our immuno-oncology programs,” said Jeffrey Hanke, Ph.D., Executive Vice President, Research and Development, and Chief Scientific Officer of TESARO.  “WuXi’s state-of-the-art, full-service biologics platform enabled us to quickly produce clinical supply of TSR-022 in support of our IND submission.”

"WuXi congratulates our partner for completing this submission. We are very pleased to have completed this critical project from DNA to IND in an expedited manner, which manifested our strong value proposition as a global integrated biologics solution provider,” said Dr. Chris Chen, CEO of WuXi Biologics.

“Congratulations to TESARO on this great progress in the important field of immuno-oncology,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec.  “We are honored to play a role to support innovative partners like TESARO through WuXi’s integrated, open-access R&D services platform, and we wish the program great clinical success.”

About WuXi AppTec

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi AppTec’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information please visit: http://www.wuxiapptec.com.

About WuXi Biologics

WuXi Biologics, a WuXi AppTec company, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi’s Biologics services, please visit: http://www.wuxibiologics.com.

For more information, please contact:

WuXi AppTec

Aaron Shi
Director of Corporate Communications

WuXi Biologics

Ms. Jia Li 
Senior Manager of Corporate Communications

back to top